glp-1 agonists reduce inflammation receptor show evidence of reducing #Psoriasis severity and systemic in patients with #obesity or #diabetes, with a favorable safety profile and compatibility with standard therapies. https://t.co/aMBllABaVT GLP-1 Receptor Agonists: A New

Its drawn to sites of injury and inflammation

( a ) Fasting plasma GIP (CON n = 11, Gipr AP-KO n = 12), ( b ) total GLP-1 (CON n = 11, Gipr AP-KO n = 12) ( c ) insulin (CON n = 11, Gipr AP-KO n = 12), ( d ) food intake post IPGTT, ( e ) ad lib fed blood glucose, ( f ) RER, ( g ) energy expenditure (inset, with ANCOVA using BW as covariate), ( h ) ambulatory activity (x beam breaks) of std chow fed (lean) mice ( d - h : CON n = 11, Gipr AP-KO n = 13, symbols as defined in f)

For example, Integrative Therapeutics advises: Take 1 capsule twice daily, or as recommended by your healthcare professional. Do not exceed the recommended dose on the label, and consult a doctor if you plan a high dose

Chicago Greenwood, Michael